Patent Publication Number: US-2010119513-A1

Title: Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS 
     This application is a divisional of U.S. Ser. No. 11/400,825, filed Apr. 7, 2006, which is a divisional of U.S. Ser. No. 10/455,720, filed Jun. 5, 2003, now issued as U.S. Pat. No. 7,067,630, which is a divisional of U.S. Ser. No. 09/650,371, filed on Aug. 28, 2000, now issued as U.S. Pat. No. 6,942,978 which is a divisional of U.S. Ser. No. 09/518,046, filed Mar. 2, 2000, now issued as U.S. Pat. No. 6,294,663, which is a continuation-in-part of U.S. Ser. No. 09/261,416, filed Mar. 3, 1999, now issued as U.S. Pat. No. 6,291,663. 
    
    
     BACKGROUND OF THE INVENTION 
     1. Field of the Invention 
     The present invention relates generally to the fields of cellular biology and diagnosis of neoplastic disease. More specifically, the present invention relates to a transmembrane serine protease termed Tumor Associated Differentially-Expressed Gene-12 (TADG-12), which is overexpressed in ovarian carcinoma. 
     2. Description of the Related Art 
     Tumor cells-rely on the expression of a concert of proteases to be released from their primary sites and move to distant sites to inflict lethality. This metastatic nature is the result of an aberrant expression pattern of proteases by tumor cells and also by stromal cells surrounding the tumors (1-3). For most tumors to become metastatic, they must degrade their surrounding extracellular matrix components, degrade basement membranes to gain access to the bloodstream or lymph system, and repeat this process in reverse fashion to settle in a secondary host site (3-6). All of these processes rely upon what now appears to be a synchronized protease cascade. In addition, tumor cells use the power of proteases to activate growth and angiogenic factors that allow the tumor to grow progressively (1). Therefore, much research has been aimed at the identification of tumor-associated proteases and the inhibition of these enzymes for therapeutic means. More importantly, the secreted nature and/or high level expression of many of these proteases allows for their detection at aberrant levels in patient serum, e.g. the prostate-specific antigen (PSA), which allows for early diagnosis of prostate cancer (7). 
     Proteases have been associated directly with tumor growth, shedding of tumor cells and invasion of target organs. Individual classes of proteases are involved in, but not limited to 1) the digestion of stroma surrounding the initial tumor area, 2) the digestion of the cellular adhesion molecules to allow dissociation of tumor cells; and 3) the invasion of the basement membrane for metastatic growth and the activation of both tumor growth factors and angiogenic factors. 
     For many forms of cancer, diagnosis and treatment has improved dramatically in the last 10 years. However, the five year survival rate for ovarian cancer remains below 50% due in large part to the vague symptoms which allow for progression of the disease to an advanced stage prior to diagnosis (8). Although the exploitation of the CA125 antigen has been useful as a marker for monitoring recurrence of ovarian cancer, it has not proven to be an ideal marker for early diagnosis. Therefore, new markers that may be secreted or released from cells and which are highly expressed by ovarian tumors could provide a useful tool for the early diagnosis and for therapeutic intervention in patients with ovarian carcinoma. 
     The prior art is deficient in the lack of identification of the proteases overexpressed in carcinoma, therefore, deficient in the lack of a tumor marker useful as an indicator of early disease, particularly for ovarian cancers. Specifically, TADG-12, a transmembrane serine protease, has not been previously identified in either nucleic acid or protein form. The present invention fulfills this long-standing need and desire in the art. 
     SUMMARY OF THE INVENTION 
     The present invention discloses TADG-12, a new member of the Tumor Associated Differentially-Expressed Gene (TADG) family, and a variant splicing form of TADG-12 (TADG-12V) that could lead to a truncated protein product. TADG-12 is a transmembrane serine protease overexpressed in ovarian carcinoma. The entire cDNA of TADG-12 has been identified (SEQ ID NO: 1). This sequence encodes a putative protein of 454 amino acids (SEQ ID NO: 2) which includes a potential transmembrane domain, an LDL receptor like domain, a scavenger receptor cysteine rich domain, and a serine protease domain. These features imply that TADG-12 is expressed at the cell surface, and it may be used as a molecular target for therapy or a diagnostic marker. 
     In one embodiment of the present invention, there is provided a DNA fragment encoding a TADG-12 protein selected from the group consisting of: (a) an isolated DNA fragment which encodes a TADG-12 protein; (b) an isolated DNA fragment which hybridizes to isolated DNA fragment of (a) above and which encodes a TADG-12 protein; and (c) an isolated DNA fragment differing from the isolated DNA fragments of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-12 protein. Specifically, the DNA fragment has a sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3. 
     In another embodiment of the present invention, there is provided a vector/host cell capable of expressing the DNA of the present invention. 
     In yet another embodiment of the present invention, there is provided an isolated and purified TADG-12 protein encoded by DNA selected from the group consisting of: (a) isolated DNA which encodes a TADG-12 protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a TADG-12 protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-12 protein. Specifically, the TADG-12 protein has an amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4. 
     In still yet another embodiment of the present invention, there is provided a method for detecting expression of a TADG-12 protein, comprising the steps of: (a) contacting mRNA obtained from the cell with the labeled hybridization probe; and (b) detecting hybridization of the probe with the mRNA. 
     The present invention further provides methods for diagnosing a cancer or other malignant hyperplasia by detecting the TADG-12 protein or mRNA disclosed herein. 
     In still another embodiment of the present invention, there is provided a method of inhibiting expression of endogenous TADG-12 mRNA in a cell by introducing a vector into the cell, wherein the vector comprises a DNA fragment of TADG-12 in opposite orientation operably linked to elements necessary for expression. In still yet another embodiment of the present invention, there is provided a method of inhibiting expression of a TADG-12 protein in a cell by introducing an antibody directed against a TADG-12 protein or fragment thereof. In still yet another embodiment of the present invention, there is provided a method of targeted therapy by administering a compound having a targeting moiety specific for a TADG-12 protein and a therapeutic moiety. Specifically, the TADG-12 protein has an amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4. 
     The present invention still further provides a method of vaccinating an individual against TADG-12 by inoculating the individual with a TADG-12 protein or fragment thereof. Specifically, the TADG-12 protein has an amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4. The TADG-12 fragment includes the truncated form of TADG-12V peptide having a sequence shown in SEQ ID NO: 8, and a 9-residue up to 12-residue fragment of TADG-12 protein. 
     In yet another embodiment of the present invention, there is provided an immunogenic composition, comprising an immunogenic fragment of a TADG-12 protein and an appropriate adjuvant. The TADG-12 fragment includes the truncated form of TADG-12V peptide having a sequence shown in SEQ ID NO: 8, and a 9-residue up to 12-residue fragment of TADG-12 protein. 
     Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
       So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope. 
         FIG. 1A  shows that the expected PCR product of approximately 180 bp and the unexpected PCR product of approximately 300 bp using the redundant serine protease primers were not amplified from normal ovary cDNA (Lane 1) but were found in abundance from ovarian tumor cDNA (Lane 2). The primer sequences for the PCR reactions are indicated by horizontal arrows.  FIG. 1B  shows that TADG-12 was subcloned from the 180 bp band while the larger 300 bp band was designated TADG-12V. The sequences were found to overlap for 180 bp (SEQ ID NO: 5 for nucleotide sequence, SEQ ID NO: 6 for deduced amino acid sequence) with the 300 bp TADG-12V (SEQ ID NO: 7 for nucleotide sequence, SEQ ID NO: 8 for deduced amino acid sequence) having an additional insert of 133 bases. This insertion (vertical arrow) leads to a frame shift, which causes the TADG-12V transcript to potentially produce a truncated form of TADG-12 with a variant amino acid sequence. 
         FIG. 2  shows that Northern blot analysis for TADG-12 revealed three transcripts of 2.4, 1.6 and 0.7 kilobases. These transcripts were found at significant levels in ovarian tumors and cancer cell lines, but the transcripts were found only at low levels in normal ovary. 
         FIG. 3  shows an RNA dot blot (CLONTECH) probed for TADG-12. The transcript was detectable (at background levels) in all 50 of the human tissues represented with the greatest abundance of transcript in the heart. Putamen, amygdala, kidney, liver, small intestine, skeletal muscle, and adrenal gland were also found to have intermediate levels of TADG-12 transcript. 
         FIGS. 4A-4C  show the entire cDNA sequence for TADG-12 (SEQ ID NO: 1) with its predicted open reading frame of 454 amino acids (SEQ ID NO: 2). Within the nucleotide sequence, the Kozak&#39;s consensus sequence for the initiation of translation and the poly-adenylation signal are underlined. In the protein sequence, a potential transmembrane domain is boxed. The LDLR-A domain is underlined with a solid line. The SRCR domain is underlined with a broken line. The residues of the catalytic triad of the serine protease domain are circled, and the beginning of the catalytic domain is marked with an arrow designated as a potential proteolytic cleavage site. The * represents the stop codon that terminates translation. 
         FIG. 5A  shows the 35 amino acid LDLR-A domain of TADG-12 (SEQ ID NO: 13) aligned with other LDLR-A motifs from the serine protease TMPRSS2 (U75329, SEQ ID NO: 14), the complement subunit C8 (P07358, SEQ ID NO: 9), two LDLR-A domains of the glycoprotein GP300 (P98164, SEQ ID Nos. 11-12), and the serine protease matriptase (AF118224, SEQ ID NO: 10). TADG-12 has its highest similarity with the other serine proteases for which it is 54% similar to TMPRSS2 and 53% similar to matriptase. The highly conserved cysteine residues are shown in bold type.  FIG. 5B  shows the SRCR domain of TADG-12 (SEQ ID NO: 17) aligned with other domain family members including the human macrophage scavenger receptor (P21757, SEQ ID NO: 16), human enterokinase (P98073, SEQ ID NO: 19), bovine enterokinase (P21758, SEQ ID NO: 15), and the serine protease TMPRSS2 (SEQ ID NO: 18). Again, TADG-12 shows its highest similarity within this region to the protease TMPRSS2 at 43%.  FIG. 5C  shows the protease domain of TADG-12 (SEQ ID NO: 23) in alignment with other human serine proteases including protease M (U62801, SEQ ID NO: 20), trypsinogen I (P07477, SEQ ID NO: 21), plasma kallikrein (P03952, SEQ ID NO: 22), hepsin (P05981, SEQ ID NO: 25), and TMPRSS2 (SEQ ID NO: 24). Cons represents the consensus sequence for each alignment. 
         FIG. 6  shows semi-quantitative PCR analysis that was performed for TADG-12 (upper panel) and TADG-12V (lower panel). The amplification of TADG-12 or TADG-12V was performed in parallel with PCR amplification of β-tubulin product as an internal control. The TADG-12 transcript was found to be overexpressed in 41 of 55 carcinomas. The TADG-12V transcript was found to be overexpressed in 8 of 22 carcinomas examined. Note that the samples in the upper panel are not necessarily the same as the samples in the lower panel. 
         FIGS. 7A-7C  show immunohistochemical staining of normal ovary and ovarian tumors which were performed using a polyclonal rabbit antibody developed to a TADG-12 specific peptide. No significant staining was detected in normal ovary ( FIG. 7A ). Strong positive staining was observed in 22 of 29 carcinomas examined.  FIGS. 7B and 7C  represent a serous and mucinous carcinoma, respectively. Both show diffuse staining throughout the cytoplasm of tumor cells while stromal cells remain relatively unstained. 
         FIG. 8  is a model to demonstrate the progression of TADG-12 within a cellular context. In normal circumstances, the TADG-12 transcript is appropriately spliced and the resulting protein is capable of being expressed at the cell surface where the protease may be cleaved to an active form. The role of the remaining ligand binding domains has not yet been determined, but one can envision their potential to bind other molecules for activation, internalization or both. The TADG-12V transcript, which occurs in some tumors, may be the result of mutation and/or poor mRNA processing may be capable of producing a truncated form of TADG-12 that does not have a functional protease domain. In addition, this truncated product may present a novel epitope at the surface of tumor cells. 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     To examine the serine proteases expressed by ovarian cancers, a PCR based differential display technique was employed utilizing redundant PCR primers designed to the most highly conserved amino acids in these proteins [9]. As a result, a novel cell-surface, multi-domain serine protease, named Tumor Associated Differentially-expressed Gene-12 (TADG-12) was identified. TADG-12 appears to be overexpressed in many ovarian tumors. The extracellular nature of TADG-12 may render tumors susceptible to detection via a TADG-12 specific assay. In addition, a splicing variant of TADG-12, named TADG-12V, was detected at elevated levels in 35% of the tumors that were examined. TADG-12V encodes a truncated form of TADG-12 with an altered amino acid sequence that may be a unique tumor specific target for future therapeutic approaches. 
     The TADG-12 cDNA is 2413 base pairs long (SEQ ID NO: 1) encoding a 454 amino acid protein (SEQ ID NO: 2). A variant form, TADG-12V (SEQ ID NO: 3), encodes a 294 amino acid protein (SEQ ID NO: 4). The availability of the TADG-12 and/or TADG-12V gene opens the way for a number studies that can lead to various applications. For example, the TADG-12 and/or TADG-12V gene can be used as a diagnostic or therapeutic target in ovarian carcinoma and other carcinomas including breast, prostate, lung and colon. 
     In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Maniatis, Fritsch &amp; Sambrook, “Molecular Cloning: A Laboratory Manual (1982); “DNA Cloning: A Practical Approach,” Volumes I and II (D. N. Glover ed. 1985); “Oligonucleotide Synthesis” (M. J. Gait ed. 1984); “Nucleic Acid Hybridization” [B. D. Hames &amp; S. J. Higgins eds. (1985)]; “Transcription and Translation” [B. D. Hames &amp; S. J. Higgins eds. (1984)]; “Animal Cell Culture” [R. I. Freshney, ed. (1986)]; “Immobilized Cells And Enzymes” [IRL Press, (1986)]; B. Perbal, “A Practical Guide To Molecular Cloning” (1984). 
     Therefore, if appearing herein, the following terms shall have the definitions set out below. 
     As used herein, the term “cDNA” shall refer to the DNA copy of the mRNA transcript of a gene. As used herein, the term “derived amino acid sequence” shall mean the amino acid sequence determined by reading the triplet sequence of nucleotide bases in the cDNA. As used herein the term “screening a library” shall refer to the process of using a labeled probe to check whether, under the appropriate conditions, there is a sequence complementary to the probe present in a particular DNA library. In addition, “screening a library” could be performed by PCR. As used herein, the term “PCR” refers to the polymerase chain reaction that is the subject of U.S. Pat. Nos. 4,683,195 and 4,683,202 to Mullis, as well as other improvements now known in the art. 
     The amino acid described herein are preferred to be in the “L” isomeric form. However, residues in the “D” isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property of immunoglobulin-binding is retained by the polypeptide. NH 2  refers to the free amino group present at the amino terminus of a polypeptide. COON refers to the free carboxy group present at the carboxy terminus of a polypeptide. In keeping with standard polypeptide nomenclature ( J Biol. Chem ., (1969) 243:3552-59), abbreviations for amino acid residues are known in the art. It should be noted that all amino-acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues. 
     A “replicon” is any genetic element, e.g., plasmid, chromosome, or virus, that functions as an autonomous unit of DNA replication in vivo; i.e., capable of replication under its own control. A “vector” is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment. A “DNA molecule” refers to the polymeric form of deoxyribonucleotides, i.e., adenine, guanine, thymine, or cytosine, in its either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules, e.g., restriction fragments, viruses, plasmids, and chromosomes. In discussing the structure herein according to the normal convention of giving only the sequence in the 5′ to 3′ direction along the nontranscribed strand of DNA, i.e., the strand having a sequence homologous to the mRNA. 
     An “origin of replication” refers to those DNA sequences that participate in DNA synthesis. A DNA “coding sequence” is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5′ (amino) terminus and a translation stop codon at the 3′ (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic, e.g., mammalian, DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3′ to the coding sequence. Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell. 
     A “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream, or 3′ direction, coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3′ terminus by the transcription initiation site and extends upstream, or 5′ direction, to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site, as well as protein binding domains or consensus sequences responsible for the binding of RNA polymerase. Eukaryotic promoters often, but not always, contain “TATA” boxes and “CAT” boxes. Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences. An “expression control sequence” is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is “under the control” of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence. 
     A “signal sequence” can be included near the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes. The term “oligonucleotide”, as used herein in referring to the probe of the present invention, is defined as a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide. 
     The term “primer” as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and use the method. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides. 
     The primers herein are selected to be “substantially” complementary to different strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5′ end of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementary with the sequence or hybridize therewith and thereby form the template for the synthesis of the extension product. 
     As used herein, the terms “restriction endonucleases” and “restriction enzymes” refer to enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence. 
     A cell has been “transformed” by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A “clone” is a population of cells derived from a single cell or ancestor by mitosis. A “cell line” is a clone of a primary cell that is capable of stable growth in vitro for many generations. 
     Two DNA sequences are “substantially homologous” when at least about 75%, preferably at least about 80% and most preferably at least about 90% or 95%, of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., supra; DNA Cloning, Vols. I &amp; II, supra; Nucleic Acid Hybridization, supra. 
     A “heterologous” region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. In another example, coding sequence is a construct where the coding sequence itself is not found in nature, e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene. Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein. 
     The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate. Proteins can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from  3 H,  14 C,  32 P,  35 S,  36 Cl,  51 Cr,  57 Co,  58 Co,  59 Fe,  90 Y,  125 I,  131 I, and  186 Re. 
     Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized. The preferred are peroxidase, b-glucuronidase, b-D-glucosidase, b-D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Pat. Nos. 3,654,090, 3,850,752, and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods. 
     A particular assay system developed and utilized in the art is known as a receptor assay. In a receptor assay, the material to be assayed is appropriately labeled and then certain cellular test colonies are inoculated with a quantity of both the label after which binding studies are conducted to determine the extent to which the labeled material binds to the cell receptors. In this way, differences in affinity between materials can be ascertained. An assay useful in the art is known as a “cis/trans” assay. Briefly, this assay employs two genetic constructs, one of which is typically a plasmid that continually expresses a particular receptor of interest when transfected into an appropriate cell line, and the second of which is a plasmid that expresses a reporter such as luciferase, under the control of a receptor/ligand complex. Thus, for example, if it is desired to evaluate a compound as a ligand for a particular receptor, one of the plasmids would be a construct that results in expression of the receptor in the chosen cell line, while the second plasmid would possess a promoter linked to the luciferase gene in which the response element to the particular receptor is inserted. If the compound under test is an agonist for the receptor, the ligand will complex with the receptor, and the resulting complex will bind the response element and initiate transcription of the luciferase gene. The resulting chemiluminescence is then measured photometrically, and dose response curves are obtained and compared to those of known ligands. The foregoing protocol is described in detail in U.S. Pat. No. 4,981,784. 
     As used herein, the term “host” is meant to include not only prokaryotes but also eukaryotes such as yeast, plant and animal cells. A recombinant DNA molecule or gene which encodes a human TADG-12 protein of the present invention can be used to transform a host using any of the techniques commonly known to those of ordinary skill in the art. Especially preferred is the use of a vector containing coding sequences for the gene which encodes a human TADG-12 protein of the present invention for purposes of prokaryote transformation. Prokaryotic hosts may include  E. coli, S. tymphimurium, Serratia marcescens  and  Bacillus subtilis . Eukaryotic hosts include yeasts such as  Pichia pastoris , mammalian cells and insect cells. In general, expression vectors containing promoter sequences which facilitate the efficient transcription of the inserted DNA fragment are used in connection with the host. The expression vector typically contains an origin of replication, promoter(s), terminator(s), as well as specific genes which are capable of providing phenotypic selection in transformed cells. The transformed hosts can be fermented and cultured according to means known in the art to achieve optimal cell growth. 
     The invention includes a substantially pure DNA encoding a TADG-12 protein, a strand of which DNA will hybridize at high stringency to a probe containing a sequence of at least 15 consecutive nucleotides of the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3. The protein encoded by the DNA of this invention may share at least 80% sequence identity, preferably 85%, more preferably 90%, and most preferably 95%, with the amino acids listed in SEQ ID NO: 2 or SEQ ID NO: 4. More preferably, the DNA includes the coding sequence of the nucleotides of  FIGS. 4A-4C  (SEQ ID NO: 1), or a degenerate variant of such a sequence. 
     The probe to which the DNA of the invention hybridizes preferably consists of a sequence of at least 20 consecutive nucleotides, more preferably 40 nucleotides, even more preferably 50 nucleotides, and most preferably 100 nucleotides or more up to 100% of the coding sequence of the nucleotides listed in  FIGS. 4A-4C  (SEQ ID NO: 1) or the complement thereof. Such a probe is useful for detecting expression of TADG-12 in a human cell by a method including the steps of (a) contacting mRNA obtained from the cell with the labeled hybridization probe; and (b) detecting hybridization of the probe with the mRNA. 
     This invention also includes a substantially pure DNA containing a sequence of at least 15 consecutive nucleotides, preferably 20, more preferably 30, even more preferably 50, and most preferably all of the region from nucleotides 1 to 2413 of the nucleotides listed in SEQ ID NO: 1, or of the region from nucleotides 1 to 2544 of the nucleotides listed in SEQ ID NO: 3. The present invention also comprises antisense oligonucleotides directed against this novel DNA. Given the teachings of the present invention, a person having ordinary skill in this art would readily be able to develop antisense oligonucleotides directed against this DNA. 
     By “high stringency” is meant DNA hybridization and wash conditions characterized by high temperature and low salt concentration, e.g., wash conditions of 65° C. at a salt concentration of approximately 0.1×SSC, or the functional equivalent thereof. For example, high stringency conditions may include hybridization at about 42° C. in the presence of about 50% formamide; a first wash at about 65° C. with about 2×SSC containing 1% SDS; followed by a second wash at about 65° C. with about 0.1×SSC. 
     By “substantially pure DNA” is meant DNA that is not part of a milieu in which the DNA naturally occurs, by virtue of separation (partial or total purification) of some or all of the molecules of that milieu, or by virtue of alteration of sequences that flank the claimed DNA. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule, e.g., a cDNA or a genomic or cDNA fragment produced by polymerase chain reaction (PCR) or restriction endonuclease digestion, independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence, e.g., a fusion protein. Also included is a recombinant DNA which includes a portion of the nucleotides shown in SEQ ID NO: 3 which encodes an alternative splice variant of TADG-12 (TADG-12V). 
     The DNA may have at least about 70% sequence identity to the coding sequence of the nucleotides listed in SEQ ID NO: 1 or SEQ ID NO: 3, preferably at least 75%, e.g. at least 80%, and most preferably at least 90%. The identity between two sequences is a direct function of the number of matching or identical positions. When a subunit position in both of the two sequences is occupied by the same monomeric subunit, e.g., if a given position is occupied by an adenine in each of two DNA molecules, then they are identical at that position. For example, if 7 positions in a sequence 10 nucleotides in length are identical to the corresponding positions in a second 10-nucleotide sequence, then the two sequences have 70% sequence identity. The length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 100 nucleotides. Sequence identity is typically measured using sequence analysis software, e.g., Sequence Analysis Software Package of the Genetics Computer Group (University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705). 
     The present invention comprises a vector comprising a DNA sequence which encodes a human TADG-12 protein and the vector is capable of replication in a host which comprises, in operable linkage: a) an origin of replication; b) a promoter; and c) a DNA sequence coding for said protein. Preferably, the vector of the present invention contains a portion of the DNA sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3. A “vector” may be defined as a replicable nucleic acid construct, e.g., a plasmid or viral nucleic acid. Vectors may be used to amplify and/or express nucleic acid encoding a TADG-12 protein. An expression vector is a replicable construct in which a nucleic acid sequence encoding a polypeptide is operably linked to suitable control sequences capable of effecting expression of the polypeptide in a cell. The need for such control sequences will vary depending upon the cell selected and the transformation method chosen. Generally, control sequences include a transcriptional promoter and/or enhancer, suitable mRNA ribosomal binding sites, and sequences which control the termination of transcription and translation. Methods which are well known to those skilled in the art can be used to construct expression vectors containing appropriate transcriptional and translational control signals. See for example, the techniques described in Sambrook et al., 1989 , Molecular Cloning: A Laboratory Manual  (2nd Ed.), Cold Spring Harbor Press, N.Y. A gene and its transcription control sequences are defined as being “operably linked” if the transcription control sequences effectively control the transcription of the gene. Vectors of the invention include, but are not limited to, plasmid vectors and viral vectors. Preferred viral vectors of the invention are those derived from retroviruses, adenovirus, adeno-associated virus, SV40 virus, or herpes viruses. 
     By a “substantially pure protein” is meant a protein which has been separated from at least some of those components which naturally accompany it. Typically, the protein is substantially pure when it is at least 60%, by weight, free from the proteins and other naturally-occurring organic molecules with which it is naturally associated in vivo. Preferably, the purity of the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight. A substantially pure TADG-12 protein may be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic acid encoding an TADG-12 polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., column chromatography such as immunoaffinity chromatography using an antibody specific for TADG-12, polyacrylamide gel electrophoresis, or HPLC analysis. A protein is substantially free of naturally associated components when it is separated from at least some of those contaminants which accompany it in its natural state. Thus, a protein which is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be, by definition, substantially free from its naturally associated components. Accordingly, substantially pure proteins include eukaryotic proteins synthesized in  E. coli , other prokaryotes, or any other organism in which they do not naturally occur. 
     In addition to substantially full-length proteins, the invention also includes fragments, e.g., antigenic fragments, of the TADG-12 protein. As used herein, “fragment,” as applied to a polypeptide, will ordinarily be at least 10 residues, more typically at least 20 residues, and preferably at least 30, e.g., 50, residues in length, but less than the entire, intact sequence. Fragments of the TADG-12 protein can be generated by methods known to those skilled in the art, e.g., by enzymatic digestion of naturally occurring or recombinant TADG-12 protein, by recombinant DNA techniques using an expression vector that encodes a defined fragment of TADG-12, or by chemical synthesis. The ability of a candidate fragment to exhibit a characteristic of TADG-12, e.g., binding to an antibody specific for TADG-12, can be assessed by methods described herein. Purified TADG-12 or antigenic fragments of TADG-12 can be used to generate new antibodies or to test existing antibodies, e.g., as positive controls in a diagnostic assay, by employing standard protocols known to those skilled in the art. Included in this invention are polyclonal antisera generated by using TADG-12 or a fragment of TADG-12 as the immunogen in, e.g., rabbits. Standard protocols for monoclonal and polyclonal antibody production known to those skilled in this art are employed. The monoclonal antibodies generated by this procedure can be screened for the ability to identify recombinant TADG-12 cDNA clones, and to distinguish them from known cDNA clones. 
     Further included in this invention are TADG-12 proteins which are encoded at least in part by portions of SEQ ID NO: 1 or SEQ ID NO: 3, e.g., products of alternative mRNA splicing or alternative protein processing events, or in which a section of TADG-12 sequence has been deleted. The fragment, or the intact TADG-12 polypeptide, may be covalently linked to another polypeptide, e.g. which acts as a label, a ligand or a means to increase antigenicity. 
     The invention also includes a polyclonal or monoclonal antibody which specifically binds to TADG-12. The invention encompasses not only an intact monoclonal antibody, but also an immunologically-active antibody fragment, e.g., a Fab or (Fab) 2  fragment; an engineered single chain Fv molecule; or a chimeric molecule, e.g., an antibody which contains the binding specificity of one antibody, e.g., of murine origin, and the remaining portions of another antibody, e.g., of human origin. 
     In one embodiment, the antibody, or a fragment thereof, may be linked to a toxin or to a detectable label, e.g. a radioactive label, non-radioactive isotopic label, fluorescent label, chemiluminescent label, paramagnetic label, enzyme label, or colorimetric label. Examples of suitable toxins include diphtheria toxin,  Pseudomonas  exotoxin A, ricin, and cholera toxin. Examples of suitable enzyme labels include malate hydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, alcohol dehydrogenase, alpha-glycerol phosphate dehydrogenase, triose phosphate isomerase, peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, acetylcholinesterase, etc. Examples of suitable radioisotopic labels include  3 H,  125 I,  13I I,  32 P,  35 S,  14 C, etc. 
     Paramagnetic isotopes for purposes of in vivo diagnosis can also be used according to the methods of this invention. There are numerous examples of elements that are useful in magnetic resonance imaging. For discussions on in vivo nuclear magnetic resonance imaging, see, for example, Schaefer et al., (1989)  JACC  14, 472-480; Shreve et al., (1986)  Magn. Reson. Med.  3, 336-340; Wolf, G. L., (1984)  Physiol. Chem. Phys. Med. NMR  16, 93-95; Wesbey et al., (1984)  Physiol. Chem. Phys. Med. NMR  16, 145-155; Runge et al., (1984)  Invest. Radiol.  19, 408-415. Examples of suitable fluorescent labels include a fluorescein label, an isothiocyalate label, a rhodamine label, a phycoerythrin label, a phycocyanin label, an allophycocyanin label, an ophthaldehyde label, a fluorescamine label, etc. Examples of chemiluminescent labels include a luminal label, an isoluminal label, an aromatic acridinium ester label, an imidazole label, an acridinium salt label, an oxalate ester label, a luciferin label, a luciferase label, an aequorin label, etc. 
     Those of ordinary skill in the art will know of other suitable labels which may be employed in accordance with the present invention. The binding of these labels to antibodies or fragments thereof can be accomplished using standard techniques commonly known to those of ordinary skill in the art. Typical techniques are described by Kennedy et al., (1976)  Clin. Chim. Acta  70, 1-31; and Schurs et al., (1977)  Clin. Chim. Acta  81, 1-40. Coupling techniques mentioned in the latter are the glutaraldehyde method, the periodate method, the dimaleimide method, the m-maleimidobenzyl-N-hydroxy-succinimide ester method. All of these methods are incorporated by reference herein. 
     Also within the invention is a method of detecting TADG-12 protein in a biological sample, which includes the steps of contacting the sample with the labeled antibody, e.g., radioactively tagged antibody specific for TADG-12, and determining whether the antibody binds to a component of the sample. 
     As described herein, the invention provides a number of diagnostic advantages and uses. For example, the TADG-12 protein disclosed in the present invention is useful in diagnosing cancer in different tissues since this protein is highly overexpressed in tumor cells. Antibodies (or antigen-binding fragments thereof) which bind to an epitope specific for TADG-12, are useful in a method of detecting TADG-12 protein in a biological sample for diagnosis of cancerous or neoplastic transformation. This method includes the steps of obtaining a biological sample (e.g., cells, blood, plasma, tissue, etc.) from a patient suspected of having cancer, contacting the sample with a labeled antibody (e.g., radioactively tagged antibody) specific for TADG-12, and detecting the TADG-12 protein using standard immunoassay techniques such as an ELISA. Antibody binding to the biological sample indicates that the sample contains a component which specifically binds to an epitope within TADG-12. 
     Likewise, a standard Northern blot assay can be used to ascertain the relative amounts of TADG-12 mRNA in a cell or tissue obtained from a patient suspected of having cancer, in accordance with conventional Northern hybridization techniques known to those of ordinary skill in the art. This Northern assay uses a hybridization probe, e.g. radiolabelled TADG-12 cDNA, either containing the full-length, single stranded DNA having a sequence complementary to SEQ ID NO: 1 or SEQ ID NO: 3, or a fragment of that DNA sequence at least 20 (preferably at least 30, more preferably at least 50, and most preferably at least 100 consecutive nucleotides in length). The DNA hybridization probe can be labeled by any of the many different methods known to those skilled in this art. 
     Antibodies to the TADG-12 protein can be used in an immunoassay to detect increased levels of TADG-12 protein expression in tissues suspected of neoplastic transformation. These same uses can be achieved with Northern blot assays and analyses. 
     The present invention is directed to DNA fragment encoding a TADG-12 protein selected from the group consisting of: (a) an isolated DNA fragment which encodes a TADG-12 protein; (b) an isolated DNA fragment which hybridizes to isolated DNA fragment of (a) above and which encodes a TADG-12 protein; and (c) an isolated DNA fragment differing from the isolated DNA fragments of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-12 protein. Preferably, the DNA has the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3. More preferably, the DNA encodes a TADG-12 protein having the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4. The present invention is also directed to a vector and/or a host cell capable of expressing the DNA of the present invention. Preferably, the vector contains DNA encoding a TADG-12 protein having the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4. Representative host cells include bacterial cells, yeast cells, mammalian cells and insect cells. 
     The present invention is also directed to an isolated and purified TADG-12 protein coded for by DNA selected from the group consisting of: (a) isolated DNA which encodes a TADG-12 protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a TADG-12 protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-12 protein. Preferably, the isolated and purified TADG-12 protein has the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4. 
     The present invention is also directed to a method of detecting expression of the TADG-12 protein described herein, comprising the steps of: (a) contacting mRNA obtained from the cell with the labeled hybridization probe; and (b) detecting hybridization of the probe with the mRNA. 
     A number of potential applications are possible for the TADG-12 gene and gene product including the truncated product TADG-12V. In one embodiment of the present invention, there is provided a method for diagnosing a cancer by detecting a TADG-12 protein in a biological sample, wherein the presence or absence of a TADG-12 protein indicates the presence or absence of a cancer. Preferably, the biological sample is selected from the group consisting of blood, urine, saliva, tears, interstitial fluid, ascites fluid, tumor tissue biopsy and circulating tumor cells. Still preferably, the detection of TADG-12 protein is by means selected from the group consisting of Northern blot, Western blot, PCR, dot blot, ELIZA sandwich assay, radioimmunoassay, DNA array chips and flow cytometry. Such method is used for detecting an ovarian cancer, breast cancer, lung cancer, colon cancer, prostate cancer and other cancers in which TADG-12 is overexpressed. 
     In another embodiment of the present invention, there is provided a method for detecting malignant hyperplasia by detecting a TADG-12 protein or TADG-12 mRNA in a biological sample. Further by comprising the TADG-12 protein or TADG-12 mRNA to reference information, a diagnosis or a treatment can be provided. Preferably, PCR amplification is used for detecting TADG-12 mRNA, wherein the primers utilized are selected from the group consisting of SEQ ID Nos. 28-31. Still preferably, detection of a TADG-12 protein is by immunoaffinity to an antibody directed against a TADG-12 protein. 
     In still another embodiment of the present invention, there is provided a method of inhibiting expression of endogenous TADG-12 mRNA in a cell by introducing a vector comprising a DNA fragment of TADG-12 in opposite orientation operably linked to elements necessary for expression. As a result, the vector produces TADG-12 antisense mRNA in the cell, which hybridizes to endogenous TADG-12 mRNA, thereby inhibiting expression of endogenous TADG-12 mRNA. 
     In still yet another embodiment of the present invention, there is provided a method of inhibiting expression of a TADG-12 protein by introducing an antibody directed against a TADG-12 protein or fragment thereof. As a result, the binding of the antibody to the TADG-12 protein or fragment thereof inhibits the expression of the TADG-12 protein. 
     TADG-12 gene products including the truncated form can be used for targeted therapy. Specifically, a compound having a targeting moiety specific for a TADG-12 protein and a therapeutic moiety is administered to an individual in need of such treatment. Preferably, the targeting moiety is selected from the group consisting of an antibody directed against a TADG-12 protein and a ligand or ligand binding domain that binds a TADG-12 protein. The TADG-12 protein has an amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4. Still preferably, the therapeutic moiety is selected from the group consisting of a radioisotope, a toxin, a chemotherapeutic agent, an immune stimulant and a cytotoxic agent. Such method can be used for treating an individual having a disease selected from the group consisting of ovarian cancer, lung cancer, prostate cancer, colon cancer and other cancers in which TADG-12 is overexpressed. 
     In yet another embodiment of the present invention, there is provided a method of vaccinating, or producing an immune response in, an individual against TADG-12 by inoculating the individual with a TADG-12 protein or fragment thereof. Specifically, the TADG-12 protein or fragment thereof lacks TADG-12 activity, and the inoculation elicits an immune response in the individual, thereby vaccinating the individual against TADG-12. Preferably, the individual has a cancer, is suspected of having a cancer or is at risk of getting a cancer. Still preferably, TADG-12 protein has an amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4, while TADG-12 fragment has a sequence shown in SEQ ID NO: 8, or is a 9-residue fragment up to a 20-residue fragment. Examples of 9-residue fragment are shown in SEQ ID Nos. 35, 36, 55, 56, 83, 84, 97, 98, 119, 120, 122, 123 and 136. 
     In still yet another embodiment of the present invention, there is provided an immunogenic composition, comprising an immunogenic fragment of a TADG-12 protein and an appropriate adjuvant. Preferably, the immunogenic fragment of the TADG-12 protein has a sequence shown in SEQ ID NO: 8, or is a 9-residue fragment up to a 20-residue fragment. Examples of 9-residue fragment are shown in SEQ ID Nos. 35, 36, 55, 56, 83, 84, 97, 98, 119, 120, 122, 123 and 136. 
     The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. 
     Example 1 
     Tissue Collection and Storage 
     Upon patient hysterectomy, bilateral salpingo-oophorectomy, or surgical removal of neoplastic tissue, the specimen is retrieved and placed on ice. The specimen was then taken to the resident pathologist for isolation and identification of specific tissue samples. Finally, the sample was frozen in liquid nitrogen, logged into the laboratory record and stored at −80° C. Additional specimens were frequently obtained from the Cooperative Human Tissue Network (CHTN). These samples were prepared by the CHTN and shipped on dry ice. Upon arrival, these specimens were logged into the laboratory record and stored at −80° C. 
     Example 2 
     mRNA Extraction and cDNA Synthesis 
     Sixty-nine ovarian tumors (4 benign tumors, 10 low malignant potential tumors and 55 carcinomas) and 10 normal ovaries were obtained from surgical specimens and frozen in liquid nitrogen. The human ovarian carcinoma cell lines SW 626 and Caov 3, the human breast carcinoma cell lines MDA-MB-231 and MDA-MB-435S were purchased from the American Type Culture Collection (Rockville, Md.). Cells were cultured to sub-confluency in Dulbecco&#39;s modified Eagle&#39;s medium, supplemented with 10% (v/v) fetal bovine serum and antibiotics. 
     Extraction of mRNA and cDNA synthesis were carried out by the methods described previously (14-16). mRNA was isolated by using a RiboSep mRNA isolation kit (Becton Dickinson Labware). In this procedure, poly A+ mRNA was isolated directly from the tissue lysate using the affinity chromatography media oligo(dT) cellulose. cDNA was synthesized with 5.0 μg of mRNA by random hexamer priming using 1st strand cDNA synthesis kit (CLONTECH). 
     Example 3 
     PCR with Redundant Primers and Cloning of TADG-12 cDNA 
     Redundant primers, forward 5′-TGGGTIGTIACIGCIGCICA(CT)TG-3′ (SEQ ID NO: 26) and reverse 5′-A(AG)IA(AG)IGCIATITCITTICC-3′ (SEQ ID NO: 27), for the consensus sequences of amino acids surrounding the catalytic triad for serine proteases were used to compare the PCR products from normal and carcinoma cDNAs. The appropriate bands were ligated into Promega T-vector plasmid and the ligation product was used to transform JM109 cells (Promega) grown on selection media. After selection of individual colonies, they were cultured and plasmid DNA was isolated by means of the Wizard miniprep DNA purification system (Promega). Nucleotide sequencing was performed using PRISM Ready Reaction Dye Deoxy terminator cycle sequencing kit (Applied Biosystems). Applied Biosystems Model 373A DNA sequencing system was used for direct cDNA sequence determination. 
     The original TADG-12 subclone was randomly labeled and used as a probe to screen an ovarian tumor cDNA library by standard hybridization techniques (11, 15). The library was constructed in λZAP using mRNA isolated from the tumor cells of a stage III/grade III ovarian adenocarcinoma patient. Three overlapping clones were obtained which spanned 2315 nucleotides. The final 99 nucleotides encoding the most 3′ sequence including the poly A tail was identified by homology with clones available in the GenBank EST database. 
     Example 4 
     Quantitative PCR 
     The mRNA overexpression of TADG-12 was determined using a quantitative PCR. Quantitative PCR was performed according to the procedure as previously reported (16). Oligonucleotide primers were used for: TADG-12, forward 5′-GAAACATGTCCTTGCTCTCG-3′ (SEQ ID NO: 28) and reverse 5′-ACTAACTTCCACAGCCTCCT-3′ (SEQ ID NO: 29); the variant TADG-12, forward 5′-TCCAGGTGGGTCTAGTTTCC-3′ (SEQ ID NO: 30), reverse 5′-CTCTTTGGCTTGTACTTGCT-3′ (SEQ ID NO: 31); β-tubulin, forward 5′-CGCATCAACGTGTACTACAA-3′ (SEQ ID NO: 32) and reverse 5′-TACGAGCTGGTGGACTGAGA-3′ (SEQ ID NO: 33). β-tubulin was utilized as an internal control. The PCR reaction mixture consists of cDNA derived from 50 ng of mRNA, 5 pmol of sense and antisense primers for both the TADG-12 gene and the β-tubulin gene, 200 μmol of dNTPs, 5 μCi of α- 32 PdCTP and 0.25 unit of Taq DNA polymerase with reaction buffer (Promega) in a final volume of 25 μl. The target sequences were amplified in parallel with the β-tubulin gene. Thirty cycles of PCR were carried out in a Thermal Cycler (Perkin-Elmer Cetus). Each cycle of PCR included 30 seconds of denaturation at 94% C, 30 seconds of annealing at 60% C and 30 seconds of extension at 72% C. The PCR products were separated on 2% agarose gels and the radioactivity of each PCR product was determined by using a Phospho Imager (Molecular Dynamics). The present study used the expression ratio (TADG-12/β-tubulin) as measured by phosphoimager to evaluate gene expression and defined the value at mean+2SD of normal ovary as the cut-off value to determine overexpression. The student&#39;s t test was used for comparison of the mean values of normal ovary and tumors. 
     Example 5 
     Sequencing of TADG-12/TADG-12V 
     Utilizing a plasmid specific primer near the cloning site, sequencing reactions were carried out using PRISM™ Ready Reaction Dye Deoxy™ terminators (Applied Biosystems NO: 401384) according to the manufacturer&#39;s instructions. Residual dye terminators were removed from the completed sequencing reaction using a Centri-sep™ spin column (Princeton Separation NO: CS-901). An Applied Biosystems Model 373A DNA Sequencing System was available and was used for sequence analysis. 
     Example 6 
     Antibody Production 
     Polyclonal rabbit antibodies were generated by immunization of white New Zealand rabbits with a poly-lysine linked multiple antigen peptide derived from the TADG-12 carboxy-terminal protein sequence NH 2 -WIHEQMERDLKT-COOH (WIHEQMERDLKT, SEQ ID NO: 34). This peptide is present in full length TADG-12, but not TADG-12V. Rabbits were immunized with approximately 100 μg of peptide emulsified in Ribi adjuvant. Subsequent boost immunizations were carried out at 3 and 6 weeks, and rabbit serum was isolated 10 days after the boost inoculations. Sera were tested by dot blot analysis to determine affinity for the TADG-12 specific peptide. Rabbit pre-immune serum was used as a negative control. 
     Example 7 
     Northern Blot Analysis 
     10 μg of mRNA were loaded onto a 1% formaldehyde-agarose gel, electrophoresed and blotted on a Hybond-N+nylon membrane (Amersham).  32 P-labeled cDNA probes were made by Prime-a-Gene Labeling System (Promega). The PCR products amplified by the same primers as above were used for probes. The blots were prehybridized for 30 min and hybridized for 60 min at 68% C with  32 P-labeled cDNA probe in ExpressHyb Hybridization Solution (CLONTECH). Control hybridization to determine relative gel loading was performed with the β-tubulin probe. 
     Normal human tissues; spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocyte, and normal human fetal tissues; brain, lung, liver and kidney (Human Multiple Tissue Northern Blot; CLONTECH) were also examined by same hybridization procedure. 
     Example 8 
     Immunohistochemistry 
     Immunohistochemical staining was performed using a Vectastain Elite ABC Kit (Vector). Formalin fixed and paraffin embedded specimens were routinely deparaffinized and processed using microwave heat treatment in 0.01 M sodium citrate buffer (pH 6.0). The specimens were incubated with normal goat serum in a moist chamber for 30 minutes. TADG-12 peptide antibody was allowed to incubate with the specimens in a moisture chamber for 1 hour. Excess antibody was washed away with phosphate buffered saline. After incubation with biotinylated anti-rabbit IgG for 30 minutes, the sections were then incubated with ABC reagent (Vector) for 30 minutes. The final products were visualized using the AEC substrate system (DAKO) and sections were counterstained with hematoxylin before mounting. Negative controls were performed by using normal serum instead of the primary antibody. 
     Example 9 
     Isolation of Catalytic Domain Subclones of TADG-12 and TADG-12 Variant 
     To identify serine proteases that are expressed in ovarian tumors, redundant PCR primers designed to the conserved regions of the catalytic triad of these enzymes were employed. A sense primer designed to the region surrounding the conserved histidine and an anti-sense primer designed to the region surrounding the conserved aspartate were used in PCR reactions with either normal ovary or ovarian tumor cDNA as template. In the reaction with ovarian tumor cDNA, a strong product band of the expected size of approximately 180 bp was observed as well as an unexpected PCR product of approximately 300 bp which showed strong expression in some ovarian tumor cDNA&#39;s ( FIG. 1A ). Both of these PCR products were subcloned and sequenced. The sequence of the subclones from the 180 bp band (SEQ ID NO: 5) was found to be homologous to the sequence identified in the larger, unexpected band (SEQ ID NO: 7) except that the larger band had an additional insert of 133 nucleotides ( FIG. 1B ). The smaller product of the appropriate size encoded for a protein sequence (SEQ ID NO: 6) homologous to other known proteases while the sequence with the insertion (SEQ ID NO: 8) encoded for a frame shift from the serine protease catalytic domain and a subsequent premature translational stop codon. TADG-12 variants from four individual tumors were also subcloned and sequenced. It was found that the sequence and insert to be identical. The genomic sequences for these cDNA derived clones were amplified by PCR, examined and found to contain potential AG/GT splice sites that would allow for the variant transcript production (data not shown). 
     Example 10 
     Northern Blot Analysis of TADG-12 Expression 
     To examine transcript size and tissue distribution, the catalytic domain subclone was randomly labeled and used to probe Northern blots representing normal ovarian tissue, ovarian tumors and the cancer cell lines SW626, CAOV3, HeLa, MD-MBA-435S and MD-MBA-231 ( FIG. 2 ). Three transcripts of 2.4, 1.6 and 0.7 kilobases were observed. In blots of normal and ovary tumor the smallest transcript size 0.7 kb was lowly expressed in normal ovary while all transcripts (2.4, 1.6 and 0.7 kb) were abundantly present in serous carcinoma. In addition, Northern blots representing the normal human tissues spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocyte, and normal human fetal tissues of brain, lung, liver and kidney were examined. The same three transcripts were found to be expressed weakly in all of these tissues (data not shown). A human β-tubulin specific probe was utilized as a control for relative sample loading. In addition, an RNA dot blot was probed representing 50 human tissues and determined that this clone is weakly expressed in all tissues represented ( FIG. 3 ). It was found most prominently in heart, with intermediate levels in putamen, amygdala, kidney, liver, small intestine, skeletal muscle, and adrenal gland. 
     Example 11 
     Sequencing and Characterization of TADG-12 
     An ovarian tumor cDNA library constructed in λZAP was screened by standard hybridization techniques using the catalytic domain subclone as a probe. Two clones that overlapped with the probe were identified and sequenced and found to represent 2316 nucleotides. The 97 nucleotides at the 3′ end of the transcript including the poly-adenylation signal and the poly (A) tail were identified by homology with clones available in GenBank&#39;s EST database. This brought the total size of the transcript to 2413 bases (SEQ ID NO: 1,  FIGS. 4A-4C ). Subsequent screening of GenBank&#39;s Genomic Database revealed that TADG-12 is homologous to a cosmid from chromosome 17. This cosmid has the accession number AC015555. 
     The identified cDNA includes an open reading frame that would produce a predicted protein of 454 amino acids (SEQ ID NO: 2), named Tumor Associated Differentially-Expressed Gene 12 (TADG-12). The sequence has been submitted to the GenBank database and granted the accession no. AF201380. Using homology alignment programs, this protein contains several domains including an amino-terminal cytoplasmic domain, a potential Type II transmembrane domain followed by a low-density lipoprotein receptor-like class A domain (LDLR-A), a scavenger receptor cysteine rich domain (SRCR), and an extracellular serine protease domain. 
     As predicted by the ™Pred program, TADG-12 contains a highly hydrophobic stretch of amino acids that could serve as a potential transmembrane domain, which would retain the amino terminus of the protein within the cytoplasm and expose the ligand binding domains and protease domain to the extracellular space. This general structure is consistent with other known transmembrane proteases including hepsin (17), and TMPRSS2 (18), and TADG-12 is particularly similar in structure to the TMPRSS2 protease. 
     The LDLR-A domain of TADG-12 is represented by the sequence from amino acid 74 to 108 (SEQ ID NO: 13). The LDLR-A domain was originally identified within the LDL Receptor (19) as a series of repeated sequences of approximately 40 amino acids, which contained 6 invariant cysteine residues and highly conserved aspartate and glutamate residues. Since that initial identification, a host of other genes have been identified which contain motifs homologous to this domain (20). Several proteases have been identified which contain LDLR-A motifs including matriptase, TMPRSS2 and several complement components. A comparison of TADG-12 with other known LDLR-A domains is shown in  FIG. 5A . The similarity of these sequences range from 44 to 54% of similar or identical amino acids. 
     In addition to the LDLR-A domain, TADG-12 contains another extracellular ligand binding domain with homology to the group A SRCR family. This family of protein domains typically is defined by the conservation of 6 cysteine resides within a sequence of approximately 100 amino acids (23). The SRCR domain of TADG-12 is encoded by amino acids 109 to 206 (SEQ ID NO: 17), and this domain was aligned with other SRCR domains and found to have between 36 and 43% similarity ( FIG. 5B ). However, TADG-12 only has 4 of the 6 conserved cysteine residues. This is similar to the SRCR domain found in the protease TMPRSS2. 
     The TADG-12 protein also includes a serine protease domain of the trypsin family of proteases. An alignment of the catalytic domain of TADG-12 with other known proteases is shown in  FIG. 5C . The similarity among these sequence ranges from 48 to 55%, and TADG-12 is most similar to the serine protease TMPRSS2 which also contains a transmembrane domain, LDLR-A domain and an SRCR domain. There is a conserved amino acid motif (RIVGG; SEQ ID NO. 154) downstream from the SRCR domain that is a potential cleavage/activation site common to many serine proteases of this family (25). This suggests that TADG-12 is trafficked to the cell surface where the ligand binding domains are capable of interacting with extracellular molecules and the protease domain is potentially activated. TADG-12 also contains conserved cysteine residues (amino acids 208 and 243) which in other proteases form a disulfide bond capable of linking the activated protease to the other extracellular domains. 
     Example 12 
     Quantitative PCR Characterization of the Alternative Transcript 
     The original TADG-12 subclone was identified as highly expressed in the initial redundant-primer PCR experiment. The TADG-12 variant form (TADG-12V) with the insertion of 133 bp was also easily detected in the initial experiment. To identify the frequency of this expression and whether or not the expression level between normal ovary and ovarian tumors was different, a previously authenticated semi-quantitative PCR technique was employed (16). The PCR analysis co-amplified a product for β-tubulin with either a product specific to TADG-12 or TADG-12V in the presence of a radiolabelled nucleotide. The products were separated by agarose gel electrophoresis and a phosphoimager was used to quantitate the relative abundance of each PCR product. Examples of these PCR amplification products are shown for both TADG-12 and TADG-12V in  FIG. 6 . Normal expression was defined as the mean ratio of TADG-12 (or TADG-12V) to β-tubulin +/−2SD as examined in normal ovarian samples. For tumor samples, overexpression was defined as &gt;2SD from the normal TADG-12/β-tubulin or TADG-12V/β-tubulin ratio. The results are summarized in Table 1 and Table 2. TADG-12 was found to be overexpressed in 41 of 55 carcinomas examined while the variant form was present at aberrantly high levels in 8 of 22 carcinomas. As determined by the student&#39;s t test, these differences were statistically significant (p&lt;0.05). 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Frequency of Overexpression of TADG-12 in Ovarian Carcinoma 
               
            
           
           
               
               
               
            
               
                   
                 Histology Type 
                 TADG-12 (%) 
               
               
                   
                   
               
            
           
           
               
               
               
               
            
               
                   
                 Normal 
                 0/16 
                 (0%) 
               
               
                   
                 LMP-Serous 
                 3/6 
                 (50%) 
               
               
                   
                 LMP-Mucinous 
                 0/4 
                 (0%) 
               
               
                   
                 Serous Carcinoma 
                 23/29 
                 (79%) 
               
               
                   
                 Mucinous Carcinoma 
                 7/12 
                 (58%) 
               
               
                   
                 Endometrioid Carcinoma 
                 8/8 
                 (100%) 
               
               
                   
                 Clear Cell Carcinoma 
                 3/6 
                 (50%) 
               
               
                   
                 Benign Tumors 
                 3/4 
                 (75%) 
               
               
                   
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 Frequency of Overexpression of TADG-12V in Ovarian Carcinoma 
               
            
           
           
               
               
               
            
               
                   
                 Histology Type 
                 TADG-12V (%) 
               
               
                   
                   
               
            
           
           
               
               
               
               
            
               
                   
                 Normal 
                 0/10 
                 (0%) 
               
               
                   
                 LMP-Serous 
                 0/5 
                 (0%) 
               
               
                   
                 LMP-Mucinous 
                 0/3 
                 (0%) 
               
               
                   
                 Serous Carcinoma 
                 4/14 
                 (29%) 
               
               
                   
                 Mucinous Carcinoma 
                 3/5 
                 (60%) 
               
               
                   
                 Endometrioid Carcinoma 
                 1/3 
                 (33%) 
               
            
           
           
               
               
               
            
               
                   
                 Clear Cell Carcinoma 
                 N/D 
               
               
                   
                   
               
               
                   
                 Overexpression = more than two standard deviations above the mean for normal ovary; LMP = low malignant potential tumor 
               
            
           
         
       
     
     Example 13 
     Immunohistochemical Analysis of TADG-12 in Ovarian Tumor Cells 
     In order to examine the TADG-12 protein, polyclonal rabbit anti-sera to a peptide located in the carboxy-terminal amino acid sequence was developed. These antibodies were used to examine the expression level of the TADG-12 protein and its localization within normal ovary and ovarian tumor cells by immuno-localization. No staining was observed in normal ovarian tissues ( FIG. 7A ) while significant staining was observed in 22 of 29 tumors studied. Representative tumor samples are shown in  FIGS. 7B and 7C . It should be noted that TADG-12 is found in a diffuse pattern throughout the cytoplasm indicative of a protein in a trafficking pathway. TADG-12 is also found at the cell surface in these tumor samples as expected. It should be noted that the antibody developed and used for immunohistochemical analysis would not detect the TADG-12V truncated protein. 
     The results of the immunohistochemical staining are summarized in Table 3. 22 of 29 ovarian tumors showed positive staining of TADG-12, whereas normal ovarian surface epithelium showed no expression of the TADG-12 antigen. 8 of 10 serous adenocarcinomas, 8 of 8 mucinous adenocarcinomas, 1 of 2 clear cell carcinomas, and 4 of 6 endometrioid carcinomas showed positive staining. 
     
       
         
           
               
               
               
               
               
               
               
             
               
                 TABLE 3 
               
               
                   
               
               
                 Case 
                 Stage 
                 Histology 
                 Grade 
                 LN* 
                 TADG12 
                 Prognosis 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 1 
                   
                 Normal ovary 
                   
                   
                 0− 
                   
               
               
                 2 
                   
                 Normal ovary 
                   
                   
                 0− 
               
               
                 3 
                   
                 Normal ovary 
                   
                   
                 0− 
               
               
                 4 
                   
                 Mucinous B 
                   
                 ND 
                 0− 
                 Alive 
               
               
                 5 
                   
                 Mucinous B 
                   
                 ND 
                 1+ 
                 Alive 
               
               
                 6 
                 1a 
                 Serous LMP 
                 G1 
                 ND 
                 1+ 
                 Alive 
               
               
                 7 
                 1a 
                 Mucinous LMP 
                 G1 
                 ND 
                 1+ 
                 Alive 
               
               
                 8 
                 1a 
                 Mucinous CA 
                 G1 
                 ND 
                 1+ 
                 Alive 
               
               
                 9 
                 1a 
                 Mucinous CA 
                 G2 
                 ND 
                 1+ 
                 Alive 
               
               
                 10 
                 1a 
                 Endometrioid CA 
                 G1 
                 ND 
                 0− 
                 Alive 
               
               
                 11 
                 1c 
                 Serous CA 
                 G1 
                 N 
                 1+ 
                 Alive 
               
               
                 12 
                 1c 
                 Mucinous CA 
                 G1 
                 N 
                 1+ 
                 Alive 
               
               
                 13 
                 1c 
                 Mucinous CA 
                 G1 
                 N 
                 2+ 
                 Alive 
               
               
                 14 
                 1c 
                 Clear cell CA 
                 G2 
                 N 
                 0− 
                 Alive 
               
               
                 15 
                 1c 
                 Clear cell CA 
                 G2 
                 N 
                 0− 
                 Alive 
               
               
                 16 
                 2c 
                 Serous CA 
                 G3 
                 N 
                 2+ 
                 Alive 
               
               
                 17 
                 3a 
                 Mucinous CA 
                 G2 
                 N 
                 2+ 
                 Alive 
               
               
                 18 
                 3b 
                 Serous CA 
                 G1 
                 ND 
                 1+ 
                 Alive 
               
               
                 19 
                 3c 
                 Serous CA 
                 G1 
                 N 
                 0− 
                 Dead 
               
               
                 20 
                 3c 
                 Serous CA 
                 G3 
                 P 
                 1+ 
                 Alive 
               
               
                 21 
                 3c 
                 Serous CA 
                 G2 
                 P 
                 2+ 
                 Alive 
               
               
                 22 
                 3c 
                 Serous CA 
                 G1 
                 P 
                 2+ 
                 Unknown 
               
               
                 23 
                 3c 
                 Serous CA 
                 G3 
                 ND 
                 2+ 
                 Alive 
               
               
                 24 
                 3c 
                 Serous CA 
                 G2 
                 N 
                 0− 
                 Dead 
               
               
                 25 
                 3c 
                 Mucinous CA 
                 G1 
                 P 
                 2+ 
                 Dead 
               
               
                 26 
                 3c 
                 Mucinous CA 
                 G2 
                 ND 
                 1+ 
                 Unknown 
               
               
                 27 
                 3c 
                 Mucinous CA 
                 G2 
                 N 
                 1+ 
                 Alive 
               
               
                 28 
                 3c 
                 Endometrioid CA 
                 G1 
                 P 
                 1+ 
                 Dead 
               
               
                 29 
                 3c 
                 Endometrioid CA 
                 G2 
                 N 
                 0− 
                 Alive 
               
               
                 30 
                 3c 
                 Endometrioid CA 
                 G2 
                 P 
                 1+ 
                 Dead 
               
               
                 31 
                 3c 
                 Endometrioid CA 
                 G3 
                 P 
                 1+ 
                 Alive 
               
               
                 32 
                 3c 
                 Clear Cell CA 
                 G3 
                 P 
                 2+ 
                 Dead 
               
               
                   
               
               
                 LN* = Lymph Node: B = Benign; N = Negative; P = Positive; ND = Not Done 
               
            
           
         
       
     
     Example 14 
     Peptide Ranking 
     For vaccine or immune stimulation, individual 9-mers to 11-mers of the TADG-12 protein were examined to rank the binding of individual peptides to the top 8 haplotypes in the general population (27). The computer program used for this analysis can be found at www.bimas.dcrt.nih.gov/molbio/hla_bind/. Table 4 shows the peptide ranking based upon the predicted half-life of each peptide&#39;s binding to a particular HLA allele. A larger half-life indicates a stronger association with that peptide and the particular HLA molecule. The TADG-12 peptides that strongly bind to an HLA allele are putative immunogens, and are used to innoculate an individual against TADG-12. 
     
       
         
           
               
             
               
                 TABLE 4 
               
             
            
               
                   
               
               
                 TADG-12 peptide ranking 
               
            
           
           
               
               
               
               
               
            
               
                 HLA Type 
                   
                   
                 Predicted 
                 SEQ 
               
               
                 &amp; Ranking 
                 Start 
                 Peptide 
                 Dissociation 1/2   
                 ID NO: 
               
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 HLA A0201 
                   
                   
                   
                   
               
               
                 1 
                 40 
                 ILSLLPFEV 
                 685.783 
                 35 
               
               
                   
               
               
                 2 
                 144 
                 AQLGFPSYV 
                 545.316 
                 36 
               
               
                   
               
               
                 3 
                 225 
                 LLSQWPWQA 
                 63.342 
                 37 
               
               
                   
               
               
                 4 
                 252 
                 WIITAAHCV 
                 43.992 
                 38 
               
               
                   
               
               
                 5 
                 356 
                 VLNHAAVPL 
                 36.316 
                 39 
               
               
                   
               
               
                 6 
                 176 
                 LLPDDKVTA 
                 34.627 
                 40 
               
               
                   
               
               
                 7 
                 13 
                 FSFRSLFGL 
                 31.661 
                 41 
               
               
                   
               
               
                 8 
                 151 
                 YVSSDNLRV 
                 27.995 
                 42 
               
               
                   
               
               
                 9 
                 436 
                 RVTSFLDWI 
                 21.502 
                 43 
               
               
                   
               
               
                 10 
                 234 
                 SLQFQGYHL 
                 21.362 
                 44 
               
               
                   
               
               
                 11 
                 181 
                 KVTALHHSV 
                 21.300 
                 45 
               
               
                   
               
               
                 12 
                 183 
                 TALHHSVYV 
                 19.658 
                 46 
               
               
                   
               
               
                 13 
                 411 
                 RLWKLVGAT 
                 18.494 
                 47 
               
               
                   
               
               
                 14 
                 60 
                 LILALAIGL 
                 18.476 
                 48 
               
               
                   
               
               
                 15 
                 227 
                 SQWPWQASL 
                 17.977 
                 49 
               
               
                   
               
               
                 16 
                 301 
                 RLGNDIALM 
                 11.426 
                 50 
               
               
                   
               
               
                 17 
                 307 
                 ALMKLAGPL 
                 10.275 
                 51 
               
               
                   
               
               
                 18 
                 262 
                 DLYLPKSWT 
                 9.837 
                 52 
               
               
                   
               
               
                 19 
                 416 
                 LVGATSFGI 
                 9.001 
                 53 
               
               
                   
               
               
                 20 
                 54 
                 SLGIIALIL 
                 8.759 
                 54 
               
               
                   
               
               
                 HLA A0205 
                   
               
               
                 1 
                 218 
                 IVGGNMSLL 
                 47.600 
                 55 
               
               
                   
               
               
                 2 
                 60 
                 LILALAIGL 
                 35.700 
                 48 
               
               
                   
               
               
                 3 
                 35 
                 AVAAQILSL 
                 28.000 
                 56 
               
               
                   
               
               
                 4 
                 307 
                 ALMKLAGPL 
                 21.000 
                 51 
               
               
                   
               
               
                 5 
                 271 
                 IQVGLVSLL 
                 19.040 
                 57 
               
               
                   
               
               
                 6 
                 397 
                 CQGDSGGPL 
                 16.800 
                 58 
               
               
                   
               
               
                 7 
                 227 
                 SQWPWQASL 
                 16.800 
                 49 
               
               
                   
               
               
                 8 
                 270 
                 TIQVGLVSL 
                 14.000 
                 59 
               
               
                   
               
               
                 9 
                 56 
                 GIIALILAL 
                 14.000 
                 60 
               
               
                   
               
               
                 10 
                 110 
                 RVGGQNAVL 
                 14.000 
                 61 
               
               
                   
               
               
                 11 
                 181 
                 KVTALHHSV 
                 12.000 
                 45 
               
               
                   
               
               
                 12 
                 151 
                 YVSSDNLRV 
                 12.000 
                 42 
               
               
                   
               
               
                 13 
                 356 
                 VLNHAAVPL 
                 11.900 
                 39 
               
               
                   
               
               
                 14 
                 144 
                 AQLGFPSYV 
                 9.600 
                 36 
               
               
                   
               
               
                 15 
                 13 
                 FSFRSLFGL 
                 7.560 
                 41 
               
               
                   
               
               
                 16 
                 54 
                 SLGIIALIL 
                 7.000 
                 54 
               
               
                   
               
               
                 17 
                 234 
                 SLQFQGYHL 
                 7.000 
                 44 
               
               
                   
               
               
                 18 
                 217 
                 RIVGGNMSL 
                 7.000 
                 62 
               
               
                   
               
               
                 19 
                 411 
                 RLWKLVGAT 
                 6.000 
                 47 
               
               
                   
               
               
                 20 
                 252 
                 WIITAAHCV 
                 6.000 
                 38 
               
               
                   
               
               
                 HLA A1 
                   
               
               
                 1 
                 130 
                 CSDDWKGHY 
                 37.500 
                 63 
               
               
                   
               
               
                 2 
                 8 
                 AVEAPFSFR 
                 9.000 
                 64 
               
               
                   
               
               
                 3 
                 328 
                 NSEENFPDG 
                 2.700 
                 65 
               
               
                   
               
               
                 4 
                 3 
                 ENDPPAVEA 
                 2.500 
                 66 
               
               
                   
               
               
                 5 
                 98 
                 DCKDGEDEY 
                 2.500 
                 67 
               
               
                   
               
               
                 6 
                 346 
                 ATEDGGDAS 
                 2.250 
                 68 
               
               
                   
               
               
                 7 
                 360 
                 AAVPLISNK 
                 2.000 
                 69 
               
               
                   
               
               
                 8 
                 153 
                 SSDNLRVSS 
                 1.500 
                 70 
               
               
                   
               
               
                 9 
                 182 
                 VTALHHSVY 
                 1.250 
                 71 
               
               
                   
               
               
                 10 
                 143 
                 CAQLGFPSY 
                 1.000 
                 72 
               
               
                   
               
               
                 11 
                 259 
                 CVYDLYLPK 
                 1.000 
                 73 
               
               
                   
               
               
                 12 
                 369 
                 ICNHRDVYG 
                 1.000 
                 74 
               
               
                   
               
               
                 13 
                 278 
                 LLDNPAPSH 
                 1.000 
                 75 
               
               
                   
               
               
                 14 
                 426 
                 CAEVNKPGV 
                 1.000 
                 76 
               
               
                   
               
               
                 15 
                 32 
                 DADAVAAQI 
                 1.000 
                 77 
               
               
                   
               
               
                 16 
                 406 
                 VCQERRLWK 
                 1.000 
                 78 
               
               
                   
               
               
                 17 
                 329 
                 SEENFPDGK 
                 0.900 
                 79 
               
               
                   
               
               
                 18 
                 303 
                 GNDIALMKL 
                 0.625 
                 80 
               
               
                   
               
               
                 19 
                 127 
                 KTMCSDDWK 
                 0.500 
                 81 
               
               
                   
               
               
                 20 
                 440 
                 FLDWIHEQM 
                 0.500 
                 82 
               
               
                   
               
               
                 HLA A24 
                   
               
               
                 1 
                 433 
                 VYTRVTSFL 
                 280.000 
                 83 
               
               
                   
               
               
                 2 
                 263 
                 LYLPKSWTI 
                 90.000 
                 84 
               
               
                   
               
               
                 3 
                 169 
                 EFVSIDHLL 
                 42.000 
                 85 
               
               
                   
               
               
                 4 
                 217 
                 RIVGGNMSL 
                 12.000 
                 62 
               
               
                   
               
               
                 5 
                 296 
                 KYKPKRLGN 
                 12.000 
                 86 
               
               
                   
               
               
                 6 
                 16 
                 RSLFGLDDL 
                 12.000 
                 87 
               
               
                   
               
               
                 7 
                 267 
                 KSWTIQVGL 
                 11.200 
                 88 
               
               
                   
               
               
                 8 
                 81 
                 RSSFKCIEL 
                 8.800 
                 89 
               
               
                   
               
               
                 9 
                 375 
                 VYGGIISPS 
                 8.000 
                 90 
               
               
                   
               
               
                 10 
                 110 
                 RVGGQNAVL 
                 8.000 
                 91 
               
               
                   
               
               
                 11 
                 189 
                 VYVREGCAS 
                 7.500 
                 92 
               
               
                   
               
               
                 12 
                 60 
                 LILALAIGL 
                 7.200 
                 48 
               
               
                   
               
               
                 13 
                 165 
                 QFREEFVSI 
                 7.200 
                 93 
               
               
                   
               
               
                 14 
                 271 
                 IQVGLVSLL 
                 7.200 
                 57 
               
               
                   
               
               
                 15 
                 56 
                 GIIALILAL 
                 7.200 
                 60 
               
               
                   
               
               
                 16 
                 10 
                 EAPFSFRSL 
                 7.200 
                 94 
               
               
                   
               
               
                 17 
                 307 
                 ALMKLAGPL 
                 7.200 
                 51 
               
               
                   
               
               
                 18 
                 407 
                 CQERRLWKL 
                 6.600 
                 95 
               
               
                   
               
               
                 19 
                 356 
                 VLNHAAVPL 
                 6.000 
                 39 
               
               
                   
               
               
                 20 
                 381 
                 SPSMLCAGY 
                 6.000 
                 96 
               
               
                   
               
               
                 HLA B7 
                   
               
               
                 1 
                 375 
                 VYGGIISPS 
                 200.000 
                 97 
               
               
                   
               
               
                 2 
                 381 
                 SPSMLCAGY 
                 80.000 
                 98 
               
               
                   
               
               
                 3 
                 362 
                 VPLISNKIC 
                 80.000 
                 99 
               
               
                   
               
               
                 4 
                 35 
                 AVAAQILSL 
                 60.000 
                 56 
               
               
                   
               
               
                 5 
                 373 
                 RDVYGGIIS 
                 40.000 
                 100 
               
               
                   
               
               
                 6 
                 307 
                 ALMKLAGPL 
                 36.000 
                 51 
               
               
                   
               
               
                 7 
                 283 
                 APSHLVEKI 
                 24.000 
                 101 
               
               
                   
               
               
                 8 
                 177 
                 LPDDKVTAL 
                 24.000 
                 102 
               
               
                   
               
               
                 9 
                 47 
                 EVFSQSSSL 
                 20.000 
                 103 
               
               
                   
               
               
                 10 
                 110 
                 RVGGQNAVL 
                 20.000 
                 91 
               
               
                   
               
               
                 11 
                 218 
                 IVGGNMSLL 
                 20.000 
                 55 
               
               
                   
               
               
                 12 
                 36 
                 VAAQILSLL 
                 12.000 
                 104 
               
               
                   
               
               
                 13 
                 255 
                 TAAHCVYDL 
                 12.000 
                 105 
               
               
                   
               
               
                 14 
                 10 
                 EAPFSFRSL 
                 12.000 
                 94 
               
               
                   
               
               
                 15 
                 138 
                 YANVACAQL 
                 12.000 
                 106 
               
               
                   
               
               
                 16 
                 195 
                 CASGHVVTL 
                 12.000 
                 107 
               
               
                   
               
               
                 17 
                 215 
                 SSRIVGGNM 
                 10.000 
                 108 
               
               
                   
               
               
                 18 
                 298 
                 KPKRLGNDI 
                 8.000 
                 109 
               
               
                   
               
               
                 19 
                 313 
                 GPLTFNEMI 
                 8.000 
                 110 
               
               
                   
               
               
                 20 
                 108 
                 CVRVGGQNA 
                 5.000 
                 111 
               
               
                   
               
               
                 HLA B8 
                   
               
               
                 1 
                 294 
                 HSKYKPKRL 
                 80.000 
                 112 
               
               
                   
               
               
                 2 
                 373 
                 RDVYGGIIS 
                 16.000 
                 100 
               
               
                   
               
               
                 3 
                 177 
                 LPDDKVTAL 
                 4.800 
                 102 
               
               
                   
               
               
                 4 
                 265 
                 LPKSWTIQV 
                 2.400 
                 113 
               
               
                   
               
               
                 5 
                 88 
                 ELITRCDGV 
                 2.400 
                 114 
               
               
                   
               
               
                 6 
                 298 
                 KPKRLGNDI 
                 2.000 
                 109 
               
               
                   
               
               
                 7 
                 81 
                 RSSFKCIEL 
                 2.000 
                 89 
               
               
                   
               
               
                 8 
                 375 
                 VYGGIISPS 
                 2.000 
                 97 
               
               
                   
               
               
                 9 
                 79 
                 RCRSSFKCI 
                 2.000 
                 115 
               
               
                   
               
               
                 10 
                 10 
                 EAPFSFRSL 
                 1.600 
                 94 
               
               
                   
               
               
                 11 
                 215 
                 SSRIVGGNM 
                 1.000 
                 108 
               
               
                   
               
               
                 12 
                 36 
                 VAAQILSLL 
                 0.800 
                 104 
               
               
                   
               
               
                 13 
                 255 
                 TAAHCVYDL 
                 0.800 
                 116 
               
               
                   
               
               
                 14 
                 381 
                 SPSMLCAGY 
                 0.800 
                 98 
               
               
                   
               
               
                 15 
                 195 
                 CASGHVVTL 
                 0.800 
                 107 
               
               
                   
               
               
                 16 
                 362 
                 VPLISNKIC 
                 0.800 
                 99 
               
               
                   
               
               
                 17 
                 138 
                 YANVACAQL 
                 0.800 
                 106 
               
               
                   
               
               
                 18 
                 207 
                 ACGHRRGYS 
                 0.400 
                 117 
               
               
                   
               
               
                 19 
                 154 
                 SDNLRVSSL 
                 0.400 
                 118 
               
               
                   
               
               
                 20 
                 47 
                 EVFSQSSSL 
                 0.400 
                 103 
               
               
                   
               
               
                 HLA B2702 
               
               
                 1 
                 300 
                 KRLGNDIAL 
                 180.000 
                 119 
               
               
                   
               
               
                 2 
                 435 
                 TRVTSFLDW 
                 100.000 
                 120 
               
               
                   
               
               
                 3 
                 376 
                 YGGIISPSM 
                 100.000 
                 121 
               
               
                   
               
               
                 4 
                 410 
                 RRLWKLVGA 
                 60.000 
                 122 
               
               
                   
               
               
                 5 
                 210 
                 HRRGYSSRI 
                 60.000 
                 123 
               
               
                   
               
               
                 6 
                 227 
                 SQWPWQASL 
                 30.000 
                 49 
               
               
                   
               
               
                 7 
                 109 
                 VRVGGQNAV 
                 20.000 
                 124 
               
               
                   
               
               
                 8 
                 191 
                 VREGCASGH 
                 20.000 
                 125 
               
               
                   
               
               
                 9 
                 78 
                 YRCRSSFKC 
                 20.000 
                 126 
               
               
                   
               
               
                 10 
                 113 
                 GQNAVLQVF 
                 20.000 
                 127 
               
               
                   
               
               
                 11 
                 91 
                 TRCDGVSDC 
                 20.000 
                 128 
               
               
                   
               
               
                 12 
                 38 
                 AQILSLLPF 
                 20.000 
                 129 
               
               
                   
               
               
                 13 
                 211 
                 RRGYSSRIV 
                 18.000 
                 130 
               
               
                   
               
               
                 14 
                 216 
                 SRIVGGNMS 
                 10.000 
                 131 
               
               
                   
               
               
                 15 
                 118 
                 LQVFTAASW 
                 10.000 
                 132 
               
               
                   
               
               
                 16 
                 370 
                 CNHRDVYGG 
                 10.000 
                 133 
               
               
                   
               
               
                 17 
                 393 
                 GVDSCQGDS 
                 10.000 
                 134 
               
               
                   
               
               
                 18 
                 235 
                 LQFQGYHLC 
                 10.000 
                 135 
               
               
                   
               
               
                 19 
                 271 
                 IQVGLVSLL 
                 6.000 
                 57 
               
               
                   
               
               
                 20 
                 408 
                 CQERRLWKL 
                 6.000 
                 95 
               
               
                   
               
               
                 HLA B4403 
               
               
                 1 
                 427 
                 AEVNKPGVY 
                 90.000 
                 136 
               
               
                   
               
               
                 2 
                 162 
                 LEGQFREEF 
                 40.000 
                 137 
               
               
                   
               
               
                 3 
                 9 
                 VEAPFSFRS 
                 24.000 
                 138 
               
               
                   
               
               
                 4 
                 318 
                 NEMIQPVCL 
                 12.000 
                 139 
               
               
                   
               
               
                 5 
                 256 
                 AAHCVYDLY 
                 9.000 
                 140 
               
               
                   
               
               
                 6 
                 98 
                 DCKDGEDEY 
                 9.000 
                 67 
               
               
                   
               
               
                 7 
                 46 
                 FEVFSQSSS 
                 8.000 
                 141 
               
               
                   
               
               
                 8 
                 38 
                 AQILSLLPF 
                 7.500 
                 129 
               
               
                   
               
               
                 9 
                 64 
                 LAIGLGIHF 
                 7.500 
                 142 
               
               
                   
               
               
                 10 
                 192 
                 REGCASGHV 
                 6.000 
                 143 
               
               
                   
               
               
                 11 
                 330 
                 EENFPDGKV 
                 6.000 
                 144 
               
               
                   
               
               
                 12 
                 182 
                 VTALHHSVY 
                 6.000 
                 145 
               
               
                   
               
               
                 13 
                 408 
                 QERRLWKLV 
                 6.000 
                 146 
               
               
                   
               
               
                 14 
                 206 
                 TACGHRRGY 
                 4.500 
                 147 
               
               
                   
               
               
                 15 
                 5 
                 DPPAVEAPF 
                 4.500 
                 148 
               
               
                   
               
               
                 16 
                 261 
                 YDLYLPKSW 
                 4.500 
                 149 
               
               
                   
               
               
                 17 
                 33 
                 ADAVAAQIL 
                 4.500 
                 150 
               
               
                   
               
               
                 18 
                 168 
                 EEFVSIDHL 
                 4.000 
                 151 
               
               
                   
               
               
                 19 
                 304 
                 NDIALMKLA 
                 3.750 
                 152 
               
               
                   
               
               
                 20 
                 104 
                 DEYRCVRVG 
                 3.600 
                 153 
               
               
                   
               
            
           
         
       
     
     CONCLUSION 
     In this study, a serine protease was identified by means of a PCR based strategy. By Northern blot, the largest transcript for this gene is approximately 2.4 kb, and it is found to be expressed at high levels in ovarian tumors while found at minimal levels in all other tissues examined. The full-length cDNA encoding a novel multi-domain, cell-surface serine protease was cloned, named TADG-12. The 454 amino acid protein contains a cytoplasmic domain, a type II transmembrane domain, an LDLR-A domain, an SRCR domain and a serine protease domain. Using a semi-quantitative PCR analysis, it was shown that TADG-12 is overexpressed in a majority of tumors studied. Immunohistochemical staining corroborates that in some cases this protein is localized to the cell-surface of tumor cells and this suggests that TADG-12 has some extracellular proteolytic functions. Interestingly, TADG-12 also has a variant splicing form that is present in 35% of the tumors studied. This variant mRNA would lead to a truncated protein that may provide a unique peptide sequence on the surface of tumor cells. 
     This protein contains two extracellular domains which might confer unusual properties to this multidomain molecule. Although the precise role of LDLR-A function with regard to proteases remains unclear, this domain certainly has the capacity to bind calcium and other positively charged ligands (21-22). This may play an important role in the regulation of the protease or subsequent internalization of the molecule. The SRCR domain was originally identified within the macrophage scavenger receptor and functionally described to bind lipoproteins. Not only are SRCR domains capable of binding lipoproteins, but they may also bind to molecules as diverse as polynucleotides (23). More recent studies have identified members of this domain family in proteins with functions that vary from proteases to cell adhesion molecules involved in maturation of the immune system (24). In addition, TADG-12, like TMPRSS2 has only four of six cysteine residues conserved within its SRCR domain. This difference may allow for different structural features of these domains that confer unusual ligand binding properties. At this time, only the function of the CD6 encoded SRCR is well documented. In the case of CD6, the SRCR domain binds to the cell adhesion molecule ALCAM (23). This mediation of cell adhesion is a useful starting point for future research on newly identified SRCR domains, however, the possibility of multiple functions for this domain can not be overlooked. SRCR domains are certainly capable of cell adhesion type interactions, but their capacity to bind other types of ligands should be considered. 
     At this time, the precise role of TADG-12 remains unclear. Substrates have not been identified for the protease domain, nor have ligands been identified for the extracellular LDLR-A and SRCR domains.  FIG. 8  presents a working model of TADG-12 with the information disclosed in the present invention. Two transcripts are produced which lead to the production of either TADG-12 or the truncated TADG-12V proteins. Either of these proteins is potentially targeted to the cell surface. TADG-12 is capable of becoming an activated serine protease while TADG-12V is a truncated protein product that if at the cell surface may represent a tumor specific epitope. 
     The problem with treatment of ovarian cancer today remains the inability to diagnose the disease at an early stage. Identifying genes that are expressed early in the disease process such as proteases that are essential for tumor cell growth (26) is an important step toward improving treatment. With this knowledge, it may be possible to design assays to detect the highly expressed genes such as the TADG-12 protease described here or previously described proteases to diagnose these cancers at an earlier stage. Panels of markers may also provide prognostic information and could lead to therapeutic strategies for individual patients. Alternatively, inhibition of enzymes such as proteases may be an effective means for slowing progression of ovarian cancer and improving the quality of patient life. Other features of TADG-12 and TADG-12V must be considered important to future research too. The extracellular ligand binding domains are natural targets for drug delivery systems. The aberrant peptide associated with the TADG-12V protein may provide an excellent target drug delivery or for immune stimulation. 
     The following references are cited herein.
     1. Duffy, M. J., Clin. Exp. Metastasis, 10: 145-155, 1992.   2. Monsky et al., Cancer Res., 53: 3159-3164, 1993.   3. Powell et al., Cancer Res., 53: 417-422, 1993.   4. Neurath, H., The Diversity of Proteolytic Enzymes. In: R. J. Beynon and J. S. Bond (eds.), pp. 1-13, Proteolytic enzymes, Oxford: IRL Press, 1989.   5. Liotta et al., Cell, 64: 327-336, 1991.   6. Tryggvason et al., Biochem. Biophys. Acta., 907: 191-217, 1987.   7. McCormack et al., Urology, 45:729-744, 1995.   8. Landis et al., CA Cancer J. Clin., 48: 6-29, 1998.   9. Tanimoto et al., Cancer Res., 57: 2884-2887, 1997.   10. Tanimoto et al., Cancer, 86: 2074-2082, 1999.   11. Underwood et al., Cancer Res., 59:4435-4439, 1999.   12. Tanimoto et al. Tumor Biology, 22: 104-114, 2000.   13. Tanimoto et al., Proc. of the Amer. Assoc. for Canc. Research 39:648, 1998.   14. Tanimoto et al., Tumor Biology, 20: 88-98, 1999.   15. Maniatis et al., J. Molecular Cloning, p. 309-361 1982.   16. Shigemasa et al., J. Soc. Gynecol. Invest., 4:95-102, 1997.   17. Leytus et al., Biochemistry, 27: 1067-1074, 1988.   18. Paoloni-Giacobino et al., Genomics, 44: 309-320, 1997.   19. Sudhof et al., Science, 228: 815-822, 1985.   20. Daly et al., Proc. Natl. Acad. Sci. USA 92: 6334-6338, 1995.   21. Mahley, R. W., Science 240: 622-630, 1988.   22. Van Driel et al., J. Biol. Chem. 262: 17443-17449, 1987.   23. Freeman et al., Proc. Natl. Acad. Sci. USA 87: 8810-8814, 1990.   24. Aruffo et al., Immunology Today 18(10): 498-504, 1997.   25. Rawlings, N. D., and Barrett, A. J., Methods Enzymology 244: 19-61, 1994.   26. Torres-Rosado et al., Proc. Natl. Acad. Sci. USA, 90: 7181-7185, 1993.   27. J. R. Parker. Practical Computer Vision Using C. John Wiley &amp; Sons inc., New York, 1994.   

     Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. 
     One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.